AQR Capital Management
AVIR icon

AQR Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

AQR Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
247,710
+201,601
+437% +$1M ﹤0.01% 2924
2026
Q1 		$248K Buy
46,109
+31,811
+222% +$146K ﹤0.01% 3503
2025
Q4 		$51K Buy
14,298
+888
+7% +$2.82K ﹤0.01% 3509
2025
Q3 		$38.9K Buy
+13,410
New +$45.8K ﹤0.01% 3431
2024
Q4 		– Sell
-13,143
Closed -$44K – 2873
2024
Q3 		$44K Buy
+13,143
New +$47.7K ﹤0.01% 2713
2023
Q4 		– Sell
-30,353
Closed -$91.1K – 2332
2023
Q3 		$91.1K Sell
30,353
-3,237
-10% -$11K ﹤0.01% 2238
2023
Q2 		$126K Sell
33,590
-103,491
-75% -$387K ﹤0.01% 2127
2023
Q1 		$459K Sell
137,081
-13,807
-9% -$56K ﹤0.01% 1809
2022
Q4 		$726K Buy
150,888
+120,376
+395% +$609K ﹤0.01% 1676
2022
Q3 		$174K Sell
30,512
-77,785
-72% -$595K ﹤0.01% 2061
2022
Q2 		$769K Sell
108,297
-173,178
-62% -$1.18M ﹤0.01% 1524
2022
Q1 		$2.03M Buy
+281,475
New +$1.91M ﹤0.01% 1168

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AQR Capital Management's AVIR Position: Q2 2026 in Review

AQR Capital Management increased its Atea Pharmaceuticals (AVIR) stake by 437% in Q2 2026, buying an estimated $1M and bringing the position to 247,710 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2924.

AQR Capital Management first reported a position in AVIR in Q1 2022 and has held it in 12 quarters since. The position peaked at $2.03M in Q1 2022. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • AQR Capital Management held 247,710 shares of Atea Pharmaceuticals worth $1.15M as of Q2 2026.
  • AQR Capital Management bought 201,601 Atea Pharmaceuticals shares in Q2 2026, an estimated $1M.
  • Atea Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2924 holding.
  • AQR Capital Management first reported a position in Atea Pharmaceuticals in Q1 2022 and has held it in 12 quarters since.
  • AQR Capital Management's Atea Pharmaceuticals position peaked at $2.03M in Q1 2022.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.